Kadimastem And Merck Serono Sign Cooperation Deal For Drug Scanning

August 4, 2014 | Kadimastem, an Israeli stem cell technology developer, announced that it signed a cooperation deal with Merck Serono for scanning drugs as potential treatments for multiple sclerosis and other neurodegenerative diseases. Merck Serono is Merck’s biopharmaceutical division which hopes to use Kadimastem’s technology to scan potential new drugs. Kadimastem, headed by CEO Yossi Ben-Yossef, has developed technologies for stem cell differentiation for oligodendrocytes, or cells required by the brain for the production myelin for the insulation of nerve fibers.